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ABSTRACT 
Objective: The objective of the present study was to develop and validate a new liquid chromatographic technique and four new 
spectrophotometric methods for the quantitative estimation of Capecitabine. 
Methods: In the first method, the chromatographic technique was carried out in isocratic technique on Shimadzu Model CBM-20A/20 Alite HPLC 
system, equipped with SPD M20A prominence PDA detector with Zorbax C18 (150 mm × 4.6 mm i. d, 5 µm particle size) column. The method was 
optimized with a mobile phase consisting of 0.1 % Acetic acid and Acetonitrile (35:65, v/v) with flow rate 0.5 ml/min. In second, third, fourth and 
fifth methods, spectrophotometric techniques were applied. The absorption maximum (λmax) was observed at 305 nm, 305 nm, 303 nm and 297 nm 
for method B (developed in 0.1 N hydrochloric acid), C (developed in sodium acetate buffer pH 4.0), D (developed in phosphate buffer pH 7.0) and E 
(developed in borate buffer pH 9.0) respectively. Different validation parameters such as linearity, precision, accuracy, limit of detection (LOD) and 
limit of quantification (LOQ), robustness were also determined. 
Results: The linearity of the calibration curves for the analyte in the desired concentration range is good for both the HPLC (R2 = 0.9994) and UV 
methods. The LOD and LOQ were found to be 0.02354 μg/ml and 0.07162 μg/ml respectively. The % RSD values for the validation parameters 
(precision and accuracy) were less than 2.0%. 
Conclusion: The proposed chromatographic and spectrophotometric methods were validated and can be applied for the determination of 
Capecitabine in pharmaceutical formulations. 
Keywords: Capecitabine, UV spectrophotometric, Forced degradation, RP-HPLC, Method validation 
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INTRODUCTION 
Capecitabine (CTB) (fig. 1) is a fluoropyrimidine carbamate with 
antineoplastic activity, and it belongs to a class of drugs known as 
antimetabolites. It is a chemotherapeutic agent administered orally 
which is used in the treatment of metastatic breast and colorectal 
cancers. CTB is a prodrug of 5’-deoxy-5-fluorouridine (5'-DFUR), 
which is enzymatically converted to 5-fluorouracil in the tumor, 
where it inhibits DNA synthesis and slows the growth of tumor 
tissue. The activation of CTB follows a pathway with three enzymatic 
steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine 
(5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-
fluorouracil. Chemically it is 5'-deoxy-5-fluoro-N-[(pentyloxy) 
carbonyl]-cytidine with empirical formula of C15H22FN3O6 and the 













Fig. 1: Chemical structure of capecitabine 
 
Literature available from all possible scientific sources revealed that 
very few analytical methods have been evoked for the estimation of 
CTB by spectrophotometric [6-13], HPLC [14-22], visible spectroscopy 
[23] and Mass spectroscopy [24] methods. Thus, the present study 
deals with the development of a sensitive, accurate and reliable 
method for the estimation of CTB in bulk and pharmaceutical dosage 
forms using a new liquid chromatographic technique and spectro-
photometric methods in four different buffer solutions.  
MATERIALS AND METHODS  
Drugs and chemicals 
Analytical grade methanol (Merck), disodium phosphate (Na2HPO4) 
(Merck), monopotassium phosphate (KH2PO4) (Merck), boric acid, 
sodium hydroxide, and glacial acetic acid were used for the analysis. 
CTB was obtained as a gift sample from Mylan Laboratories limited. All 
the other reagents used in the analysis were of the high purity 
analytical grade. All weighing was performed on a calibrated analytical 
balance. Calibrated glassware’s were used throughout the 
experiments. 
Preparation of reagents and solutions 
Preparation of 0.1 N HCl 
For the preparation of 0.1 N HCl, 8.5 ml of HCl was diluted with 1000 
ml of distilled water. 
Preparation of sodium acetate buffer (pH 4.0) 
For the preparation of sodium acetate buffer (pH 4.0), 2.86 ml of 
glacial acetic acid and 1.0 ml of 50% w/v solution of sodium 
hydroxide was added in a 100 ml volumetric flask and made up the 
volume with HPLC grade water. 
Preparation of phosphate buffer (pH 7.0) 
For the preparation of phosphate buffer (pH 7.0), 0.5 gms of 
Na2HPO4 and 0.301 gms of KH2PO4 was added in a 1000 ml 
volumetric flask and the volume was made up with distilled water. 
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Preparation of borate buffer (pH 9.0) 
For the preparation of borate buffer (pH 9.0), 6.2 gm of boric acid 
was dissolved in 500 ml of water and the pH was adjusted to 9.0 
with 1 M sodium hydroxide (about 41.5 ml) and diluted with water 
in a 1000 ml volumetric flask. 
Preparation of stock and sample solutions 
The standard solution of CTB was prepared by dissolving accurately 
about 25 mg of the CTB with methanol in a 25 ml volumetric flask. 
The stock solution was further diluted with 0.1 N HCl, sodium 
acetate buffer (pH 4.0), phosphate buffer (pH 7.0), and borate buffer  
(pH 9.0) for method B (1-80 µg/ml), method C (1-60 µg/ml), method 
D (5-80 µg/ml), and method E (1-60 µg/ml) respectively as per the 
requirement. 
CTB stock standard solution (1 mg/ml) 
CTB stock solution (1000 μg/ml) was prepared by dissolving 25 mg 
of CTB in mobile phase in a 25 ml volumetric flask. Working 
solutions were prepared from the stock solution with mobile phase, 
and all the solutions were filtered through 0.45 μm membrane. 
Instrumentation and method development 
RP-HPLC Instrumentation and chromatographic conditions  
Chromatographic separation was achieved by using a Shimadzu 
Model CBM-20A/20 Alite HPLC system, equipped with SPD M20A 
prominence PDA detector with Zorbax C18 (150 mm × 4.6 mm i. d, 
5 µm particle size) column. A mixture of 0.1% Acetic Acid and 
acetonitrile (35:65, v/v) was used as the mobile phase. The flow 
rate was 0.5 ml/min and 20 µl of each sample was injected into the 
HPLC system. 
UV spectrophotometer instrumentation 
A double beam UV-VIS spectrophotometer (UV-1800, Shimadzu) 
loaded with spectra manager software UV Probe was employed with 
a spectral bandwidth of 1 nm and wavelength accuracy of ±0.3 nm 
with a pair of 10 mm matched quartz cells. The wavelength range of 
200 nm to 400 nm was selected for scanning with medium scanning 
speed. 
Procedure for preparation of solution for spectrophotometric 
determination 
A series of drug solutions 1-80 µg/ml, 1-60 µg/ml, 5-80 µg/ml and 1-
60 µg/ml for method B, C, D and E respectively were scanned (200-
400 nm) against their reagent blank i.e. 0.1 N HCl for method B, 
sodium acetate buffer (pH 4.0) for method C, phosphate buffer (pH 
7.0) for method D and borate buffer (pH 9.0) for method E and the 
absorption spectra were recorded. The absorption maximum (λmax) 
was observed at 305 nm, 305 nm, 303 nm and 297 nm for methods 
B, C, D and E respectively and the absorbance was recorded against 
each concentration. 
A graph was drawn by taking the concentration of the drug solutions 
on the x-axis and the corresponding absorbance values on the y-axis 
for methods B, C, D and E. 
Forced degradation studies 
Stress studies were performed to evaluate the specificity of the 
method. All the samples (1 mg/ml) were exposed to stress 
degradation conditions and diluted with mobile phase (100 μg/ml) 
and filtered prior to injection [25].  
Acid and base induced degradation products 
Acidic and alkaline degradations were performed by treating the 
drug solution (1 mg/ml) with 0.1 N hydrochloric acid and 0.1 N 
sodium hydroxide respectively. The solutions were refluxed for 1 h 
at 80 °C, cooled, neutralized and diluted with mobile phase as per 
the requirement. 
Oxidation-induced degradation products 
Oxidation degradation was performed by treating the drug solution 
(1 mg/ml) with 30% hydrogen peroxide. The solution was refluxed 
for 1 hour at 80 °C, cooled and diluted with mobile phase as per the 
requirement.  
Thermal induced degradation products 
For thermal stress testing, 1 mg/ml drug solution was heated in a 
thermostat at 80 °C for 1 hour, cooled, filtered and diluted as per the 
requirement before use. 
Method validation 
Linearity  
A series of CTB solutions 0.5–150 μg/ml were prepared from the 
stock, diluted with mobile phase and 20 µl was injected into the 
HPLC system. The peak area of each chromatogram was noted. A 
calibration curve was plotted by taking a concentration of the CTB 
solutions on the x-axis and the corresponding peak area on the y-
axis [25].  
Precision and accuracy 
The intra-day and inter-day precision of the method were calculated 
at three different concentration levels (10, 50 and 100 µg/ml) and 
on three different days respectively and the % RSD was calculated. 
The accuracy of the assay method was calculated at three different 
levels (80, 100 and 120%), and the percentage recoveries were 
calculated [25]. 
Limit of quantification (LOQ) and limit of detection (LOD)  
The limit of quantification (LOQ) and limit of detection (LOD) was 
based on the standard deviation of the response and the slope of 
the constructed calibration curve (n=3), as described in 
International Conference on Harmonization guidelines Q2 (R1) 
[17, 25]. 
Method robustness  
The robustness of the assay method was established by introducing 
small changes in the HPLC conditions which included wavelength 
(238 and 242 nm), the percentage of acetonitrile in the mobile phase 
(63 and 67%) and flow rate (0.4 and 0.6 ml/min). Robustness of the 
method was studied using three replicates at a concentration level 
100 μg/ml CTB [25].  
Assay of marketed formulations of CTB (tablet) 
CTB is available as tablets with brand names CACIT 500 (500 mg; 
BIOCHEM limited, India.), CAPEGARD (500 mg; CIPLA Ltd, India) 
CAPGET (500 mg; GLS PHARMA Ltd, India) and procured from the 
local pharmacy store. The contents of each brand of CTB equivalent 
to 10 mg was extracted with methanol, sonicated and made up to 
volume with methanol in 10 ml volumetric flasks (1 mg/ml) and 
filtered. The dilutions were made from this stock as per the 
requirement for method B, C, D and E the percentage recovery was 
calculated. 
RESULTS AND DISCUSSION 
A detailed comparative study of the previously published 
methods with the present method is discussed in table 1. The 
satisfactory resolution was achieved with the use of a mixture of 
0.1% acetic acid and acetonitrile (35:65, v/v) and C18 column 
was adopted for the analysis as it has provided a better 
separation of the analyzes. UV detection was carried out at 240 
nm (PDA detector).  
The present stability-indicating method for the determination of 
CTB in pharmaceutical formulations is specific because the drug 
peak was well separated even in the presence of degradation 
products. Overall, the data demonstrated that the excipients and 
the degradation products did not interfere with the CTB peak, 
indicating the selectivity of the method.  
The complete separation of the analytics was accomplished in 
less than 10 min and the method can be successfully applied to 
perform long-term and accelerated stability studies of CTB 
formulations. 
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Table 1: Comparative table of CTB 
Method Mobile phase Linearity Detection Reference 
UV Ethanol 5-25 307  
[6] HPLC ACN: phosphate 3.8 30-80 306 
UV water 5-25 240 [7] 
UV Water 5-40 304  
[8] Methanol 2-24 303 
Ethanol 5-25 306 
Phosphate buffer 7.4 2-38 303 
Acetonitrile 2-20 306 
Visible Iodine+HCl+PMAP+Sac 25-150 520 [23] 
Tannic acid+metal volume 10-60 560 
UV Methanol 2.5-15 243.60 [9] 
RP-HPLC 0.05M phosphate buffer (pH 3.0±0.05) buffer 
and acetonitrile (50:50 % w/v) 
70-120 240 [14] 





RP-HPLC Phosphate buffer: Acetonitrile (80:20) v/v 50-150 240 [16] 
UV Methanol 5-25 295 [10] 
RP-HPLC Methanol: buffer (70:30) 10-50  [17] 
UV Methanol 3-15 263,281,293 [11] 
RP-HPLC Methanol: buffer (45:55) 10-60  
HPTLC Chloroform: glacial acetic acid: methanol 100-600  
RP-HPLC methanol: Acetonitrile: water 
(80:18:2 V/V) 
20-120 230 [18] 
RP-HPLC Methanol: Acetonitrile: Water (50:30:20,v/v, 
pH adjusted to 4.6 using Triethylamine) 
2-10 245 [19] 
UV Phosphate 3 10-20 256.3 [13] 
UV methanol 2-10 245 [12] 
RP-HPLC-PDA Ammonium acetate: methanol (35:65 v/v) 2-10 240 [20] 
RP-HPLC 0.005 M dipotassium hydrogen rthophosphate 
(pH 6.8) and acetonitrile 70:30 v/v 
25-300 mg/ml 240 [21] 
RP-HPLC Methanol: water 20-160 271 [22] 
 
Table 2: Spectral characteristics of CTB 
Parameters Method B Method C Method D Method E 
Beer-Lambert’s limits (µg/ml) 1-80 1-60 5-80 1-60 
λmax/Amplitude range (nm) 305 305 303 297 
Molar extinction coefficient 
(Liter/mol. cm) 
88.4001 x 103 96.3058 x 103 98.4619 x 103 143.0213 x 103 
Sandell’s sensitivity (µg/cm2/0.001 absorbance unit) 0.04065 0.03731 0.03649 0.0251 
Slope 0.0238 0.0262 0.0265 0.408 
Intercept 0.0008 0.0065 0.012 0.0092 
Correlation coefficient 0.9992 0.9991 0.9999 0.9993 
 
nm.










Fig. 2A: Absorption spectrum of CTB in 0.1 N HCl 
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Spectroscopic method 
UV spectrophotometric methods were developed in HCl, sodium 
acetate buffer (pH 4.0), phosphate buffer (pH 7.0), and borate buffer 
(pH 9.0) and were recorded. Beer’s law was obeyed over the 
concentration range 1-80 µg/ml, 1-60 µg/ml, 5-80 µg/ml and 1-60 
µg/ml for the methods with regression equations 0.0238x+0.0008, 
0.262x+0.0065, 0.0265x+0.012 and 0.408x–0.0092 for methods B, C, 
D and E respectively (table 2), The resulting overlay spectra were 
shown in fig. 2A, 2B, 2C and 2D and the calibration curves obtained 
were shown in fig. 3A, 3B, 3C and 3D. The % RSD values in precision 
studies were found to be 0.31, 0.24, 0.43 and 0.22 for method B, C, D 
and E respectively (RSD<2%) indicating that the method is more 
precise. The % RSD values in accuracy studies were found to be 
0.457, 0.624, 0.384 and 0.642 for method B, C, D and E respectively 
(RSD<2%) indicating that the method is more accurate. 
 
nm.











Fig. 2B: Absorption spectrum of CTB in sodium acetate buffer (pH 4.0) 
 
nm.









Fig. 2C: Absorption spectrum of CTB in phosphate buffer (pH 7.0) 
 
nm.









Fig. 2D: Absorption spectrum of CTB in borate buffer (pH 9.0) 
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Fig. 3A: Calibration curve of CTB in 0.1 N HCl 
 
 
Fig. 3B: Calibration curve of CTB in sodium acetate buffer (pH 4.0) 
 
 
Fig. 3C: Calibration curve of CTB in phosphate buffer (pH 7.0) 
 
Fig. 3D: Calibration curve of CTB in borate buffer (pH 9.0) 
 
HPLC method development and optimization  
Initially, the pure drug sample solutions were analyzed using a 
mobile phase consisting of TBHS: acetonitrile (30:70, v/v) at a flow 
rate of 0.8 ml/min. Under these conditions, a sharp peak was 
observed at 2.089 min with fronting and the same was continued 
even though the mobile phase composition was changed to 45:55 or 
35:65 or the flow rate was changed to 0.9 ml/min. So finally the 
mobile phase was totally changed to 0.1% acetic acid: acetonitrile 
(35:65, v/v) with a flow rate of 0.5 ml/min under which peaks were 
well resolved with good symmetry with a retention time of 3.26 min. 
Therefore, the mobile phase containing 0.1% acetic acid: acetonitrile 
(35:65, v/v) was chosen as the best chromatographic response for 
the entire study.  
Forced degradation studies  
CTB standard and tablet powder was found to be quite stable under 
dry heat conditions. Major decomposition was seen on exposure of 
CTB drug solution to acidic (81.17%), alkaline (83.67%), oxidation 
(26.66%), thermal (21.44%) and photolytic (9.54%) degradations 
indicating that the drug is highly resistant towards the above 
degradations (table 3). An extra peak was observed at 2.699 min for 
acidic reaction, at 2.621 min and 2.892 min for alkaline reaction, at 2.620 
min and 4.312 min for thermal and at 2.628 min for the oxidation 
reaction. Typical chromatograms of standard and degradations studies 
of CTB are showed in fig. 4A, 4B, 4C, 4D, 4E and 4F. 
 
Table 3: Results of degradation studies 
Degradation studies *Mean peak area±SD (RSD) *Mean drug recovered (%)±SD (RSD) *Mean drug decomposed (%)±SD (RSD) 
Standard Drug 8873190.33±19453.70 (0.22) - - 
Acid 1663184.33±15863.07 (0.95) 18.75±0.18 (0.98) 81.25±0.18 (0.23) 
Alkaline 1451970.33±12129.83 (0.84) 16.37±0.13 (0.80) 83.63±0.13 (0.16) 
Oxidation 6496443.33±20476.04 (0.32) 73.25±24 (0.33) 26.75±0.24 (0.91) 
Thermal 6960681.67±4453.33 (0.06) 78.49±0.08 (0.10) 21.51±0.08 (0.37) 
U. V 8023375.00±9048.32 (0.11) 90.47±0.05 (0.06) 9.53±0.05 (0.53) 
*Each value is average of three determinations [±SD (RSD)] 
 






































Fig. 4A: Typical chromatogram of standard of CTB 
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Fig. 4B: Typical chromatogram of acid degradation of CTB 
 









































Fig. 4C: Typical chromatogram of base degradation of CTB 
 











































Fig. 4D: Typical chromatogram of thermal degradation of CTB 
 


































Fig. 4E: Typical chromatogram of oxidation degradation of CTB 
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Fig. 4F: Typical chromatogram of protolytic degradation of CTB 
 
Method validation  
System suitability  
The system suitability test was performed to ensure that the complete 
testing system was suitable for the intended application. The 
parameters measured were peak area, retention time, tailing factor, 
capacity factor and theoretical plates. In all measurements the peak 
area varied less than 2.0%, the average retention time was 3.26±0.02 
min. The capacity factor was more than 2, theoretical plates were 3500 
(more than 2000) and the tailing factor was 1.594 (less than 2) for the 
CTB peak. The LOQ was found to be 0.02354 μg/ml and the LOD was 
found to be 0.07162 μg/ml 
Linearity  
The typical chromatograms for CTB obtained from the bulk and 
extracted marketed formulations. The calibration curve for CTB was 
linear over the concentration range 0.5–150 μg/ml.  
The data for the peak area of the drug corresponding to the 
concentration was treated by linear regression analysis (table 4) and 
the regression equation for the calibration curve was found to be y = 
86247x+60749 with a correlation coefficient of 0.9994 which nearly 
equals to unity. The calibration curves obtained were shown in fig. 5. 
The % RSD range was 0.14-0.50. 
 
Table 4: Linearity results of CTB 
Conc. (μg ml-1) Mean area±SD RSD (%) 
Mean area SD 
0.5 56321 182.48 0.324 
1 84488 239.10 0.28 
5 464641 2309.27 0.50 
10 941821 3060.92 0.33 
20 1755501 4810.07 0.27 
50 4485992 6370.11 0.14 
100 8893822 22234.56 0.25 
150 12825530 60279.99 0.47 
 
 
Fig. 5: Calibration curve of CTB in 0.1% acetic acid: acetonitrile 
 
Precision  
The precision of the method was determined by repeatability 
(intraday precision) and intermediate precision (inter-day 
precision) of the CTB standard solutions. Repeatability was 
calculated by assaying three samples of each at three different 
concentration levels (20, 50 and 100 μg/ml) on the same day. The 
inter-day precision was calculated by assaying three samples of each 
at three different concentration levels (20, 50 and 100 μg/ml) on 
three different days. The % RSD range was obtained as 0.18-1.07 
and 0.72-1.39 for intra-day and inter-day precision studies 
respectively (table 5).  
Because the stability of standard solutions can also affect the 
robustness of analytical methods, the stability of standard solutions 
of the drug substance used in this method was tested over a long 
period of time (48 h). One portion of a standard solution was kept at 
room temperature, and the other portion was stored under 
refrigeration at approximately 4°C and the content of these solutions 
were regularly compared with that of freshly prepared solutions. No 
change in drug concentrations was observed for solutions stored 
under refrigeration. But it is recommended that the sample and 
standard solutions must, therefore, be freshly prepared in amber 
colored flasks to protect from light. 
Accuracy  
The method accuracy was proved by the recovery studies. A known 
amount of CTB standard (100 μg/ml) was added to aliquots of 
samples solutions and then diluted to yield total concentrations as 
90, 100 and 110 μg/ml as described in table 5. The assay was 
repeated over 3 consecutive days. The resultant % RSD was in the 
range 0.38-1.08 (<2.0 %) with a recovery 100.42-101.39 %. 
Robustness  
The robustness of an analytical procedure refers to its ability to 
remain unaffected by small and deliberate variations in method 
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parameters and provides an indication of its reliability for routine 
analysis [20]. The robustness of the method was evaluated by 
assaying the same sample under different analytical conditions 
deliberately changing from the original condition. The detection 
wavelength was set at 238 and 242 nm (±2 nm), the ratio of 
percentage of acetic acid: acetonitrile in the mobile phase was 
applied as 33:67 and 37:63 (±2 %, v/v), the flow rate was set at 0.4 
and 0.6 ml/min (±0.1 ml/min). The results obtained (table 6) from 
assay of the test solutions were not affected by varying the 
conditions and were in accordance with the results for original 
conditions. The % RSD value of assay determined for the same 
sample under original conditions and robustness conditions was less 
than 2.0% (0.12-0.62) indicating that the developed method was 
robust.
 
Table 5: Precision and accuracy 
Precision 
Conc. (µg/ml) Intra-day precision Inter-day precision 
*Mean peak area±SD (%RSD) *Mean peak area±SD (%RSD) 
20 1775623.00±17426.16 (0.98) 1748594.00±24305.13 (1.39) 
50 4477307.00±7860.14 (0.18) 4470316.33±31967.72 (0.72) 
100 8804916.33±94368.59 (1.07) 8844759.33±119575.70 (1.35) 
Accuracy 
Conc. (µg/ml) *Mean peak area±SD (% RSD) Drug found (µg/ml) *Recovery (%) 
90 7876212.33±47141.95 (0.60) 90.62 100.69 
100 8804916.33±94368.59 (1.07) 101.39 101.39 
110 9587919.00±36055.51 (0.38) 110.46 100.42 
*Each value is average of three determinations 
 
Table 6: Robustness results of CTB 
Parameter Condition *Mean peak area *Mean peak area SD RSD 
Flow rate (±0.1 ml/min) 0.4 8886535 8896003.33 10726.66 0.12 
0.5 8893822 
0.6 8907653 
Detection wavelength (±2 nm) 238 8866545 8879855.00 15282.28 0.17 
240 8896544 
242 8876476 
Mobile phase composition (water: acetonitrile) 
(±2 % v/v) 
33-67 8887646 8924681.33 55713.28 0.62 
35-65 8897644 
37-63 8988754 
*Each value is average of three determinations 
 
Table 7: Assay of commercial formulations 
Brand Labeled amount (mg) *Amount obtained (mg) % Recovery* 
  Method Method 
A B C D A B C D 
CACIT 500 499.45 494.45 496.15 495.26 99.89 98.89 99.23 99.05 
CAPEGARD 500 497.45 495.15 499.12 498.45 99.49 99.03 99.82 99.69 
CAPGET 500 494.45 490.23 492.45 494.23 98.89 98.04 98.49 98.84 
*Each value is average of three determinations 
 
Selectivity/specificity  
The specificity of the developed method was determined by injecting 
sample solutions (100 μg/ml) which were prepared by forcibly 
degrading under stress conditions such as heat, light, oxidative 
agent, acid, and base under the proposed chromatographic 
conditions. The stability indicating the capability of the method was 
established from the separation of CTB peak from the degraded 
samples. The degradation of CTB was found to be very similar for 
both the tablets and standard. 
Analysis of commercial formulations (tablets) 
The proposed method was applied for the determination of CTB in 
tablets CACIT 500 (500 mg), CAPGET (500 mg)and the results show 
98.98-99.32 % recovery (table 7) indicates that the method is 
selective for the assay of CTB without interference from the 
excipients used in these tablets. 
CONCLUSION 
The proposed stability-indicating HPLC method was validated and 
applied for the determination of CTB in pharmaceutical dosage 
forms. The method was found to be accurate, precise, robust and 
specific as the peak drug elution did not interfere with any 
degradants during the forced degradation studies and therefore the 
proposed method can be successfully applied to perform the 
analysis of the samples during the studies. 
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